Monday, December 5, 2011

- POSTER (#318): Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection
  AUTHORS: Zewdu H. Dadi, Workagegnehu Hailu, Teklu Weldegebreal, Hailemariam Tafes, Raymond Omollo, Sisay Yifru, Manica Balasegaram, Asrat Hailu
  SESSION TITLE: Poster Session 28. Poster Session A Presentations and Light Lunch
  SESSION TIME: 12:00-1:45 PM
  LOCATION: Convention Center - Ballroom AB
  LINK: [http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=3e738b4d-67ec-4083-9545-c4f1200bef50&sKey=7cb13c72-f25b-4915-b4f1-c806e3395a85](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=3e738b4d-67ec-4083-9545-c4f1200bef50&sKey=7cb13c72-f25b-4915-b4f1-c806e3395a85)

Tuesday, December 6, 2011

- SYMPOSIUM (Session # 84): A Decade Later: Drug Development and the Promise of Health Care Impact
  SESSION TIME: 10:15 AM - 12:00 PM
  SPEAKER: Monique Wasunna, DNDi Africa/KEMRI
  LOCATION: Convention Center - Room 204A
  LINK: [http://www.abstractsonline.com/Plan/ViewSession.aspx?mID=2756&sKey=d00bcb64-222c-40a6-a23f-45b41d7ea22b](http://www.abstractsonline.com/Plan/ViewSession.aspx?mID=2756&sKey=d00bcb64-222c-40a6-a23f-45b41d7ea22b)
  DETAILS:
  - Organizer: Tim Wells, MMV; Co-chair: Elizabeth Ponder (replacing Melinda Moree), BVGH
  - 10:15 AM: The role of PDPs in accelerating development of the right antimalarials for the right populations – Robert Newman, WHO
- 10:35 AM: A successful model to engage biotech companies into drug discovery for global health impact: The Human African Trypanosomiasis (HAT) Drug Discovery Program – Yves Ribeill, SCYNEXIS
- 11:20 AM: PDP Partnering to develop and monitor new treatments for malaria – an industry perspective – Silvio Gabriel, Novartis
- 11:40 AM: How regional platforms may facilitate innovation and access to new tools: The example of LEAP (Leishmaniasis East Africa) Platform – Monique Wasunna, KEMRI, DNDi

**POSTER (#849): Analogues of fenarimol as novel compounds for the treatment of Chagas disease**

AUTHORS: Martine Keenan [presenter],¹ Mike Abbott,¹ Paul Alexander,¹ Tanya Armstrong,² Wayne Best,¹ Bradley Berven,¹ Adriana Botero,² Jason Chaplin,¹ Susan Charman,³ Eric Chatelain,⁴ Hugo Diao,¹ Tom von Geldern,⁴ Maria Kerfoot,² Andrea Khong,² Joshua McManus,¹ Ivan Scandale,⁴ Andrew Thompson,² Zhisen Wang,¹ Karen White³

AFFILIATIONS: 1. Epichem, Perth, Australia; 2. School of Veterinary & Biomedical Sciences, Murdoch University, Perth, Australia; 3. CDCO, Monash University, Melbourne, Australia; 4. Drugs for Neglected Diseases initiative, Geneva, Switzerland

**4. Drugs for Neglected Diseases initiative, Geneva, Switzerland**

SESSION TITLE: Poster Session 86. Poster Session C Presentations and Light Lunch
SESSION TIME: 12:00-1:45 PM
LOCATION: Convention Center - Ballroom AB
LINK: [http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=25fe2a4c-6b0f-4015-87db-ca8d5e1827a&sKey=e085170f-1e5f-491f-99e6-cf35f6c71b8a](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=25fe2a4c-6b0f-4015-87db-ca8d5e1827a&sKey=e085170f-1e5f-491f-99e6-cf35f6c71b8a)

**POSTER (#LB-2171): Plasmodium falciparum polymorphisms and human CYP2C8 polymorphisms in clinical efficacy of artemisinin-based combination therapies in Liberia**

AUTHORS: Sabina Dahlstrom,¹ Vincent Jullien,² Oumou Maiga-Ascofare,¹ Birgit Schramm,³ Joel J. Jones,⁴ Yah M. Zolia,⁴ Elizabeth A. Ashley,³ Jean-Rene Kiechel,⁵ Philippe J. Guerin,³ Jacques Le Bras,⁵ Sandrine Houze⁷


SESSION TITLE: Poster Session 86. Poster Session C Presentations and Light Lunch
SESSION TIME: 12:00-1:45 PM
LOCATION: Convention Center - Ballroom AB
LINK: [http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=96cbf729-3c0b-4826-925f-6cc49c781eb5&sKey=e085170f-1e5f-491f-99e6-cf35f6c71b8a](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=96cbf729-3c0b-4826-925f-6cc49c781eb5&sKey=e085170f-1e5f-491f-99e6-cf35f6c71b8a)

**POSTER (#898): A systematic review and meta-analysis of non-randomized and randomized controlled studies of artesunate and amodiaquine for the treatment of uncomplicated falciparum malaria in Africa**

AUTHORS: Piero L. Olliaro,¹ Michel Vaillant,² Michael O. Harhay³

Wednesday, December 7, 2011

• SYMPOSIUM (Session # 119): CYP51 as a Target for Chagas Disease Drugs
  SESSION TIME: 8:00 - 9:45 AM
  SPEAKER: Isabela Ribeiro, DNDi Latin America
  LOCATION: Convention Center - Room 201A
  LINK: http://www.abstractsonline.com/Plan/ViewSession.aspx?mID=2756&sKey=724ec211-b459-44e3-a7b5-252c92b71679
  DETAILS:
  - Organizer: James H. McKerrow, UCSF; Co-chair: Larissa Podust, UCSF
  - 8:00 AM: CYP51 inhibitors in clinical trials for the etiological treatment of Chagas Disease – Julio Urbina, Venezuelan Institute for Scientific Research
  - 8:20 AM: Clinical trial of E1224 for treatment of Chagas disease – Isabela Ribeiro, DNDi
  - 8:40 AM: Crystallography of CYP51 to guide medicinal chemistry – Larissa Podust, UCSF
  - 9:00 AM: New drug scaffolds targeting CYP51 in T. cruzi – Martine Keenan, Murdoch University, Murdoch, Australia
  - 9:20 AM: Optimizing analogs of tipifarnib as Trypanosoma cruzi CYP51 inhibitors – Frederick S. Buckner, University of Washington, Seattle

• POSTER (#1123): Flubendazole as a potential macrofilaricidale for field use
  AUTHORS: Charles MacKenzie,1 Timothy Geary,2 Nicole Madrill,1 Carlos Lanusse,3 Robert Don4
  AFFILIATIONS: 1. Michigan State University, East Lansing, MI, United States; 2. McGill University, Montreal, Canada; 3. Universidad Nacional del Centro, Tandil, Argentina; 4. Drugs for Neglected Diseases initiative, Geneva, Switzerland
  SESSION TITLE: Poster Session 136. Poster Session D Presentations and Light Lunch
  SESSION TIME: 12:00-1:45 PM
  LOCATION: Convention Center - Ballroom AB
  LINK: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=7a41f7e1-6246-4547-a8de-e5c662f069a4&sKey=e085170f-1e5f-491f-99e6-cf35f6c71b8a

Contacts (on site): Oliver Yun, oyun@dndi.org, +1-646-266-5216; Erin Conklin-Kimaoui, econklin@dndi.org, +1-646-206-2707